moderate PROSPER project effects, as youth with the GABRA2 TT genotype, who were at higher risk in the control group, saw greater intervention-led reductions in alcohol misuse compared to youth with A genotypes, especially during early-to-mid-adolescence (ages 13–16), an important age period for the prevention of alcohol use disorders. The non-significant intervention effects across all of adolescence for GABRA2 A carriers, who were at lower risk for alcohol use in the control condition, may suggest the need for alternate or additional intervention content to reduce early and later adolescent drinking among these youth. Overall, our findings support the notion that the preventive intervention effectiveness may vary by genetic risk and age, and emphasize the need for continued research into how tailoring intervention content may help reduce the burden of alcohol use disorders in adolescence and adulthood for as many individuals as possible.
